{"name":"Fondation Ophtalmologique Adolphe de Rothschild","slug":"fondation-ophtalmologique-adolphe-de-rothschild","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"immediate treatment with corticosteroids","genericName":"immediate treatment with corticosteroids","slug":"immediate-treatment-with-corticosteroids","indication":"Acute ocular inflammation (specific indication not detailed in source)","status":"phase_3"},{"name":"injection of NMBA","genericName":"injection of NMBA","slug":"injection-of-nmba","indication":"Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation","status":"marketed"},{"name":"Administration of dornase alfa","genericName":"Administration of dornase alfa","slug":"administration-of-dornase-alfa","indication":"Cystic fibrosis","status":"phase_2"},{"name":"Budesonide Nasal","genericName":"Budesonide Nasal","slug":"budesonide-nasal","indication":"Other","status":"marketed"},{"name":"Daily infusion of dornase alfa","genericName":"Daily infusion of dornase alfa","slug":"daily-infusion-of-dornase-alfa","indication":"Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations)","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ocrelizumab Injection [Ocrevus]","genericName":"Ocrelizumab Injection [Ocrevus]","slug":"ocrelizumab-injection-ocrevus","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"Ocrelizumab Injection [Ocrevus]","genericName":"Ocrelizumab Injection [Ocrevus]","slug":"ocrelizumab-injection-ocrevus","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation and demyelination.","indications":["Relapsing-remitting multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"immediate treatment with corticosteroids","genericName":"immediate treatment with corticosteroids","slug":"immediate-treatment-with-corticosteroids","phase":"phase_3","mechanism":"Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Acute ocular inflammation (specific indication not detailed in source)"],"catalyst":""},{"name":"injection of NMBA","genericName":"injection of NMBA","slug":"injection-of-nmba","phase":"marketed","mechanism":"NMBA (neuromuscular blocking agent) injection causes temporary paralysis of skeletal muscles by blocking acetylcholine at the neuromuscular junction.","indications":["Adjunct to anesthesia to facilitate endotracheal intubation and surgical relaxation"],"catalyst":""},{"name":"Administration of dornase alfa","genericName":"Administration of dornase alfa","slug":"administration-of-dornase-alfa","phase":"phase_2","mechanism":"Dornase alfa is a recombinant form of human deoxyribonuclease I that breaks down DNA in the extracellular matrix of cystic fibrosis sputum, reducing its viscosity.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Budesonide Nasal","genericName":"Budesonide Nasal","slug":"budesonide-nasal","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Daily infusion of dornase alfa","genericName":"Daily infusion of dornase alfa","slug":"daily-infusion-of-dornase-alfa","phase":"phase_2","mechanism":"Dornase alfa is a recombinant human DNase that breaks down extracellular DNA in mucus to reduce viscosity and improve clearance.","indications":["Cystic fibrosis (investigational use in Phase 2 by Fondation Ophtalmologique Adolphe de Rothschild, likely for ocular or systemic manifestations)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5ySVV6Zjd6QU5HUE5oOE83WDJaNTUxWDJvVlh1eUdCTzJvUGdrZFVrY0k0ZWVOZUFtaGhVTDZJc1B2Tk1kbG1LVF8zblNoMHBXMldlT2g4OTFJUkYyV2VlZXpwbEwxY0p6c0o5Y3BYeDQ?oc=5","date":"2017-01-25","type":"earnings","source":"American Academy of Ophthalmology","summary":"DMEK Learning Curve and Outcomes - American Academy of Ophthalmology","headline":"DMEK Learning Curve and Outcomes","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":2,"marketed":2,"phase_2":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}